Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Nov 30:6:2073.
doi: 10.12688/f1000research.12938.2. eCollection 2017.

Dyslipidemia: Genetics, lipoprotein lipase and HindIII polymorphism

Marcos Palacio Rojas  1   2 , Carem Prieto  1 , Valmore Bermúdez  1   3 , Carlos Garicano  3 , Trina Núñez Nava  2 , María Sofía Martínez  1 , Juan Salazar  1 , Edward Rojas  4 , Arturo Pérez  4 , Paulo Marca Vicuña  2 , Natalia González Martínez  2 , Santiago Maldonado Parra  2 , Kyle Hoedebecke  5   6 , Rosanna D'Addosio  7 , Clímaco Cano  1 , Joselyn Rojas  8
Affiliations
Review

Dyslipidemia: Genetics, lipoprotein lipase and HindIII polymorphism

Marcos Palacio Rojas et al. F1000Res. .

Abstract

The direct link between lipid metabolism alterations and the increase of cardiovascular risk are well documented. Dyslipidemias, including isolated high LDL-c or mixed dyslipidemia, such as those seen in diabetes (hypertriglyceridemia, high LDL-c or low HDL-c), correlate with a significant risk of cardiovascular and cerebrovascular disease worldwide. This review analyzes the current knowledge concerning the genetic basis of lipid metabolism alterations, emphasizing lipoprotein lipase gene mutations and the HindIII polymorphism, which are associated with decreased levels of triglycerides and LDL-c, as well as higher levels of HDL-c. These patterns would be associated with decreased global morbidity and mortality, providing protection against cardiovascular and cerebrovascular diseases.

Keywords: Dyslipidemia; HindIII; Lipoprotein Lipase; Polymorphisms; coronary artery disease.

PubMed Disclaimer

Conflict of interest statement

No competing interests were disclosed.

Figures

Figure 1.
Figure 1.. Chromosomal origin of the LPL gene.
The authors confirm that this is an original image and has not been re-used or adapted from another source.
Figure 2.
Figure 2.. Recognition sequence of HindIII enzyme.
The authors confirm that this is an original image and has not been re-used or adapted from another source.
Figure 3.
Figure 3.. Intron 8, restriction site of HindIII (AAGC TT > AAGC GT).
The authors confirm that this is an original image and has not been re-used or adapted from another source.
Figure 4.
Figure 4.. Enzymatic restriction sites in HindIII .
The authors confirm that this is an original image and has not been re-used or adapted from another source.
See this image and copyright information in PMC

References

    1. Helkin A, Stein JJ, Lin S, et al. : Dyslipidemia Part 1--Review of Lipid Metabolism and Vascular Cell Physiology. Vasc Endovascular Surg. 2016;50(2):107–18. 10.1177/1538574416628654 - DOI - PubMed
    1. Murray CJ, Lopez AD: Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet. 1997;349(9061):1269–76. 10.1016/S0140-6736(96)07493-4 - DOI - PubMed
    1. Gordon DJ, Probstfield JL, Garrison RJ, et al. : High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989;79(1):8–15. 10.1161/01.CIR.79.1.8 - DOI - PubMed
    1. Isomaa B, Almgren P, Tuomi T, et al. : Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24(4):683–9. 10.2337/diacare.24.4.683 - DOI - PubMed
    1. Carr MC, Brunzell JD: Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J Clin Endocrinol Metab. 2004;89(6):2601–7. 10.1210/jc.2004-0432 - DOI - PubMed

LinkOut - more resources